West Pharmaceutical Services revenue and financials

WST · NYSE · USD

$376.76+3.23%+$11.78

Close · October 5, 2026

In the fiscal year ended December 2025, West Pharmaceutical Services reported revenue of $3.07B (+6.25% year over year). Net income was $493.7M, a net margin of 16.1%.

Annual revenue · 2025: $3.07B

$1.51B2016
$1.6B2017
$1.72B2018
$1.84B2019
$2.15B2020
$2.83B2021
$2.89B2022
$2.95B2023
$2.89B2024
$3.07B2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +6.25%; 2025 vs 2024
Net income growth: +0.20%; 2025 vs 2024
Net margin: 16.1%; 2024: 17.0%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total revenue	3,074	2,893	2,950	2,887	2,832	2,147	1,840	1,717	1,599	1,509
Cost of revenue	1,970	1,895	1,821	1,751	1,656	1,379	1,234	1,172	1,086	1,008
Gross profit	1,104	999	1,129	1,136	1,176	768	606	545	513	501
Selling, general and administrative	394	339	353	317	—	—	—	—	—	—
Research and development	74.3	69.1	68.4	58.5	52.8	46.9	38.9	40.3	39.1	36.8
Operating income	585	570	676	734	752	407	297	240	226	195
EBIT	—	589	707	688	757	—	—	—	—	—
EBITDA	773	744	844	808	—	—	—	—	—	—
Interest expense	0.5	3.0	9.0	7.9	8.2	8.2	8.5	8.4	7.8	8.1
Pre-tax income	601	586	698	680	—	—	—	—	—	—
Income tax	122	108	122	115	107	72.5	59.0	41.4	80.9	54.4
Net income	494	493	593	586	662	346	242	207	151	144
Net income to common shareholders	494	493	593	586	—	—	—	—	—	—
Basic EPS	6.83	6.75	7.98	7.87	8.89	4.68	3.27	2.80	2.04	1.96
Diluted EPS	6.79	6.69	7.88	7.73	8.67	4.57	3.21	2.74	1.99	1.91
Average shares (basic)	72.3	73.0	74.3	74.4	—	—	—	—	—	—
Average shares (diluted)	72.7	73.7	75.3	75.8	76.3	75.8	75.4	75.4	75.8	75.0